Wechselwirkungen · Abilify Maintena
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre- filled syringe Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre- filled syringe · Abschnitt 4.5 · PDF-Seite 7
HOS-129411 · Präparat HOS-096717
Due to its α1-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T15:16:00Z · SHA-256 41ea025269b746fee63511b9edbf4ea222d53988b45b27fd317f27f82cafb4fe · Passage 3f3a1d92a4ecfb74becb43f21e2bc3700bfd06145ec6892ba53dd66969ea25c6 · Zeichen 138–284 im Abschnitt